Expanded Medicare coverage for localized prostate cancer patients

 


Who

The Oncotype DX Genomic Prostate Score assay is available and fully covered by Medicare for prostate cancer patients with:
checkmark   Very Low-Risk
checkmark   Low-Risk
checkmark   Favorable Intermediate-Risk
checkmark   Unfavorable Intermediate-Risk
checkmark   High-Risk







 


WHEN

Effective Date:

Effective now


 

GPS
Benefit

Make more confident decisions about active surveillance and treatment intensity with the Oncotype DX GPS assay.

 

Actionable risk assessments for more informed treatment decisions

  • Predictive of Prostate Cancer Death and Metastasis within 10 years of receiving radical prostatectomy1
  • Predictive of Adverse Pathology2,3 the most immediate and actionable endpoint when making treatment decisions*
  • Predictive of Biochemical Recurrence within 3 years of receiving radical prostatectomy17
  • Developed, Validated and Studied in over 5,000 patients1-17
  • Medicare-Coverage for use in patients with NCCN very low-, low-, intermediate, and high-risk prostate cancer
  • Included in NCCN Guidelines® as an option to help guide management decisions16
REFERENCES

  1. Van Den Eeden et al. Eur Urol. 2017.
  2. Klein et al. Eur Urol. 2014.
  3. Cullen et al. Eur Urol. 2015.
  4. Badani et al. Urol Pract. 2015.
  5. Albala et al. Rev Urol. 2016.
  6. Dall’Era et al. Urol Pract. 2015.
  7. Knezevic et al. BMC Genomics. 2013.
  8. Lynch et al. Am J Manage Care 2018.
  9. Brand et al. Urology. 2016.
  10. Bonham et al. USCAP 2016.
  11. Salmasi et al. J Urol. 2018.
  12. Eure et al. Urology. 2017.
  13. Eure et al. AUA 2017.
  14. Leapman et al. PloS One. 2017.
  15. Cullen et al. Urology. 2020.
  16. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer.
  17. Data on file.

*Adverse pathology is provided for patients with Gleason 3+3 and 3+4 disease

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.2.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed June 1, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.

Making cancer care smarter.®